Listen to the sounds disrupting farms worldwide
A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
Search
world rabies day 2019
world rabies day 2019
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
European Metacam® indication expanded to guinea pigs
Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.